Finally the anti-CTLA4 antibody tremelimumab showed relevant results in patients with HCC and coinfection of HCV with a partial response rate of 17.6% and a disease control rate of 76.4% [32]. Here, CTLA4 is linked to hepatocellular carcinoma.